Description: CelluVir Biotechnology is dedicated to improving global health through the development of affordable and user-friendly diagnostic tools. Our mission is to revolutionize viral infection diagnostics, starting with COVID-19. All immunology experts agree that when our body combats viral infections, cell-mediated immunity plays a crucial role. While serum antibody measurements are informative in short term assessment of immunity, COVID will stay with us in some form, and we believe that testing cellular immunity will be necessary due to fading antibody levels and the emergence of new variants. Assessing cellular immunity is currently complex and costly. Existing laboratory tests for cellular immunity are mainly for research purposes, require fresh blood, specialized facilities, and trained experts, making these tests hard to access. This is where CelluVir Biotechnology comes in. We have developed an innovative test providing a point-of-care, simple, and reliable way to assess cellular immunity against COVID-19. Our test offers the missing piece of the puzzle, enabling informed decisions regarding vaccination strategies and the administration of booster shots in the years to come. Our solution is a microneedle-based skin patch test, making it simple and self-administered. The results are easy to interpret: the redness (local inflammation) of the skin in the test area after 24 hours (with a negative control) indicates a delayed type hypersensitivity reaction, confirming the presence of cellular immunity.